Back to Our Science

Cell Therapy Delivery Systems


EXUMA’s proprietary, centralized CCT3 CAR-T process is launch-ready and needs no further modifications to be commercially viable.

  • A proprietary process which could support market entry
  • 17-day vein-to-vein, fully closed, fresh in, frozen out process
  • No manufacturing failures from IIT studies in China
  • Uses real-time monitoring electronic batch record bar code system to help mitigate potential errors


rPOC subcutaneous (SC) technology could expand access to potentially life-saving CAR-based therapies while reducing costs by avoiding the need for adjuvant chemotherapy and extended hospital admissions.

  • Subcutaneously injected CAR-TaNK product can be efficiently manufactured in less than six hours
  • Potential for fewer side effects by eliminating lymphodepleting chemotherapy
  • Leveraging a unique T- and NK-like (“TaNK”) cell population generated from the technology, with properties of both T and NK cells, rPOC SC may produce lower systemic cytokine burden during expansion, while maintaining durability of anti-tumor response
  • Has potential for administration in a broader setting of care due to potential for reduced treatment-related complications